Royal Fund Management LLC Has $5.64 Million Holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI)

Royal Fund Management LLC trimmed its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 78.9% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 62,600 shares of the exchange traded fund’s stock after selling 233,886 shares during the period. Royal Fund Management LLC’s holdings in SPDR S&P Biotech ETF were worth $5,638,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bank of New York Mellon Corp raised its holdings in SPDR S&P Biotech ETF by 15.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 5,590 shares of the exchange traded fund’s stock valued at $518,000 after acquiring an additional 744 shares during the period. Envestnet Asset Management Inc. grew its position in shares of SPDR S&P Biotech ETF by 12.5% in the second quarter. Envestnet Asset Management Inc. now owns 186,400 shares of the exchange traded fund’s stock valued at $17,281,000 after purchasing an additional 20,685 shares during the last quarter. Mercer Global Advisors Inc. ADV increased its stake in shares of SPDR S&P Biotech ETF by 40.6% during the second quarter. Mercer Global Advisors Inc. ADV now owns 11,128 shares of the exchange traded fund’s stock worth $1,032,000 after purchasing an additional 3,214 shares during the period. Brighton Jones LLC acquired a new stake in SPDR S&P Biotech ETF during the 2nd quarter worth approximately $208,000. Finally, AE Wealth Management LLC boosted its stake in SPDR S&P Biotech ETF by 13.3% in the 2nd quarter. AE Wealth Management LLC now owns 11,184 shares of the exchange traded fund’s stock valued at $1,037,000 after purchasing an additional 1,314 shares during the period.

SPDR S&P Biotech ETF Price Performance

Shares of NYSEARCA XBI opened at $87.97 on Tuesday. SPDR S&P Biotech ETF has a one year low of $81.14 and a one year high of $105.47. The firm has a market cap of $6.71 billion, a price-to-earnings ratio of 11.47 and a beta of 1.11. The stock’s fifty day moving average price is $93.78 and its two-hundred day moving average price is $96.96.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.